Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Next Previous
Trial Profile

A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer; Bone metastases; HER2 negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BOLERO-2
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation

Most Recent Events

  • 22 Sep 2020 Results from NCT00073528 (n=484) and NCT00863655 (n=261 ) developing prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic HER2-negative breast cancer, published in the Clinical Cancer Research
  • 31 May 2020 Results (n=510) assessing the prognostic/predictive ability of serum biomarker, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
  • 09 Dec 2017 Results assessing the prognostic and predictive ability of activin A (n=513) presented at the 40th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top